The hallmark of cancer is uncontrolled cellular proliferation mediated by the dysregulation of cell-cycle machinery and activation of cyclin-dependent kinases (CDKs). The agents which target CDKs have been seen as encouraging therapeutic targets in cancer treatment.
Although, due to their low efficacy and adverse events, the first-generation pan-CDK inhibitors failed in clinical trials, most recently, a new generation of selective CDK4/6 inhibitors, including Abemaciclib, Ribociclib, and Palbociclib, has shown powerful efficacy with tolerable safety in preclinical and clinical studies.
CDK Inhibitors from BioVision
Recent approval of Palbociclib (Ibrance®) by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-negative and ER-positive breast cancer shows that, based on individual tumor genetics, CDK inhibitors with high selectivity profiles can have clinical utility for therapy. BioVision is proud to offer >25 potent and selective CDK inhibitors including Abemaciclib (LY-2835219), Palbociclib (PD0332991), Ribociclib, and Dinaciclib, for research.
About BioVision Incorporated
BioVision, Inc., is a privately held Life Science company headquartered in the beautiful San Francisco Bay Area.
BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision's products are currently being sold in more than 60 countries worldwide.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.